Genetic testing before therapy may be worth it in severe MDD . . .

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.638, 2011-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Testing essential if trastuzumab therapy to be worth it

By  

Inpharma, Vol. 1, Iss. 1432, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Testing essential if trastuzumab therapy to be worth it

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 449, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Amlodipine may be worth it for patients with CAD . . .

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 501, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Is genetic testing to guide cancer therapy cost effective?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 630, 2011-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Sertraline plus sleep deprivation therapy boosts QOL in MDD

By  

Inpharma, Vol. 1, Iss. 1510, 2005-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite